Pulmonary fibrosis induced by
silica dust is an irreversible, chronic, and fibroproliferative
lung disease with no effective treatment at present. BMSCs-derived exosomes (BMSCs-Exo) possess similar functions to their parent cells. In this study, we investigated the therapeutic potential and underlying molecular mechanism for BMSCs-Exo in the treatment of
silica-induced
pulmonary fibrosis. The rat model of experimental
silicosis pulmonary fibrosis was induced with 1.0 mL of one-off infusing
silica suspension using the non-exposed intratracheal instillation (50 mg/mL/rat). In vivo
transplantation of BMSCs-Exo effectively alleviated
silica-induced
pulmonary fibrosis, including a reduction in
collagen accumulation, inhibition of TGF-β1, and decreased HYP content. Treatment of BMSCs-Exo increased the expression of epithelial marker
proteins including
E-cadherin (E-cad) and cytokeratin19 (CK19) and reduced the expression of
fibrosis marker
proteins including α-Smooth muscle actin (α-SMA) after exposure to
silica suspension. Furthermore, we found that BMSCs-Exo inhibited the expression of Wnt/β-
catenin pathway components (P-GSK3β, β-
catenin,
Cyclin D1) in
pulmonary fibrosis tissue. BMSCs-Exo is involved in the alleviation of
silica-induced
pulmonary fibrosis by reducing the level of profibrotic factor TGF-β1 and inhibiting the progression of epithelial-mesenchymal transition (EMT). Additionally, attenuation of the Wnt/β-
catenin signaling pathway closely related to EMT may be one of the mechanisms involved in anti-fibrotic effects of exosomes.